ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01447342
Recruitment Status : Completed
First Posted : October 6, 2011
Last Update Posted : March 24, 2015
Sponsor:
Information provided by (Responsible Party):
MyoScience, Inc

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A prospective, non-randomized, multicenter study to evaluate the safety and effectiveness of the cryo-touch II device for the treatment of forehead and/or glabellar lines

Condition or disease Intervention/treatment Phase
Facial Wrinkles Skin Aging Device: Cryo-Touch II Phase 2 Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : September 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : August 2012
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Device: Cryo-Touch II
    Percutaneous treatment with the device

Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Effectiveness success [ Time Frame: Up to 4 months ]
    Effectiveness endpoint: wrinkle severity in the forehead in animation at 30 days post-treatment (Visit 5) as rated by the investigator/designee using the 5-point Wrinkle Scale (5WS).

  2. Safety success [ Time Frame: Up to 4 months ]
    Safety endpoint: Tolerability of treatment (LSRs), local and systemic adverse events will be assessed at all visits. Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADEs) will be recorded. A serious adverse event is one that meets the ISO definition of SAE .


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is a male or female, 30 to 70 years old.
  2. Subject is willing and able to give written informed consent.
  3. Subject has a forehead wrinkle rating by the investigator/designee of at least "2" in animation on the 5-point Wrinkle Scale (5WS) which upon physical manipulation/separation of the skin demonstrates a reduction in wrinkle severity. Subject may also have a glabellar score of "1" or higher in animation on a 4-point scale.
  4. Subject is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study.
  5. Subject is in good general health and free of any disease state or physical condition that might impair evaluation of forehead and/or glabellar wrinkle rating or which, in the investigator's opinion, exposes the subject to an unacceptable risk by study participation.

Exclusion Criteria:

  1. Subject is currently enrolled in an investigational drug or device study.
  2. Subject has used an investigational drug or investigational device treatment within 30 days prior to first administration of the device.
  3. Subject has a clotting disorder or has used an anticoagulant (e.g., Coumadin, clopidogrel, etc.) within seven (7) days prior to administration of the device.
  4. Subject has used aspirin, or non-steroidal anti-inflammatory drugs (NSAIDs, e.g., ibuprofen, and naproxen) within seven (7) days prior to administration of the device.
  5. Subject has had prior surgery that alters the subcutaneous anatomy of the target treatment sites.
  6. Subject has undergone another facial cosmetic procedure at or above the level of the cheekbones within the past six (6) months.

  7. Subject has any of the following conditions:

    1. History of facial nerve palsy,
    2. Marked facial asymmetry,
    3. Ptosis,
    4. History of neuromuscular disorder,
    5. Chronic dry eye symptoms,
    6. Allergy or intolerance to lidocaine,
    7. Other local skin condition (e.g., skin infection) at target treatment site,
    8. Any physical or psychiatric condition that in the investigator's opinion would prevent adequate study participation.
    9. Chronic medical condition that in the investigator's opinion would affect study participation (such as diabetes, hepatitis, HIV, etc.).
    10. Any chronic condition contraindicated for the use of nerve mapping device including heart disease, use of a cardiac pacemaker, and pregnancy.
  8. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01447342


Locations
United States, California
Macro, Llc
Beverly Hills, California, United States, 90212
The Aesthetics Research Center
Redwood City, California, United States, 94063
Roseville Facial Plastic Surgery
Roseville, California, United States, 95661
Sponsors and Collaborators
MyoScience, Inc
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: MyoScience, Inc
ClinicalTrials.gov Identifier: NCT01447342     History of Changes
Other Study ID Numbers: MS-4400
First Posted: October 6, 2011    Key Record Dates
Last Update Posted: March 24, 2015
Last Verified: March 2015